Jason Rhodes is a partner at Atlas Venture and focuses on creating and building novel therapeutics companies.

He is the chairman and was the founding CEO of Dyne Therapeutics (NASDAQ: DYN), Rectify Pharmaceuticals, and Generation Bio (NASDAQ: GBIO). He is also on the boards of AAVantgarde Bio, Be Biopharma, K36, and Accent Therapeutics. He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020, and was previously on the boards of Third Harmonic Bio (NASDAQ: THRD), Replimune (NASDAQ: REPL), and Bicycle Therapeutics (NASDAQ: BCYC).